Current best evidence on prescribed drugs

Drugdocs Logo

Current best evidence on prescribed drugs

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Vizimpro

Chemical Namedacomitinib
Dosage FormTablet (oral; 15 mg, 30 mg, 45 mg)
Drug ClassKinase inhibitors
SystemRespiratory
CompanyPfizer
Approval Year2018

Indication

  • Indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test
Last updated on 4/20/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Vizimpro (Dacomitinib) Prescribing Information.2018Pfizer Inc., New York, NY
Document TitleYearSource
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer.2019NICE
Final clinical guidance report: dacomitinib (Vizimpro) for non-small cell lung cancer. 2019CADTH
Final economic guidance report: dacomitinib (Vizimpro) for non-small cell lung cancer. 2019CADTH
Assessment report: Vizimpro. 2019EMA
Document TitleYearSource
Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in a Japanese population. 2021Future Oncology
Hepatotoxicity with epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancer patients: a network meta-analysis. 2021Journal of Clinical Pharmacy and Therapeutics
Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: a systematic review and network meta-analysis. 2021Critical Reviews in Oncology/Hematology
Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis. 2020BMJ
Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis.2020Lung Cancer Management
First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis. 2019OncoTargets and Therapy
Document TitleYearSource
Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. 2020EMSO
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV.2019International Journal of Clinical Oncology
SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). 2018Clinical and Translational Oncology